DPP-4 inhibitors are a class of diabetes drug that helps to increase insulin production in patients with type-2 diabetes. Popular DPP-4 inhibitors such as Januvia, known as Janumet overseas, have been linked with possible problems like pancreatitis and pancreatic cancer. However, DPP-4 inhibitors may be on the way out due to a new class of drug.
Januvia is an oral diabetes medication that earns Merck Pharmaceuticals $6 billion per year. In recent quarters, the growth for Januvia has accelerated due to the release of a study’s results presented at the American Diabetes Association and published in the New England Journal of Medicine. The study showed that Januvia met its goals of not increasing cardiovascular events compared to other DPP-4 inhibitors. The study, Trial Evaluating Cardiovascular Outcomes with Sitagliptin (the scientific name for Januvia), or TECOS, showed that there was no increase of major cardiovascular events requiring hospitalization versus the placebo.
However, DPP-4 inhibitor drugs have now met a competitor in SGLT-2 inhibitors, which work in the kidneys rather than in the pancreas. SGLT-2 inhibitors prevent the absorption of glucose in the kidneys and allow it to pass in the urine.
Eli Lilly and partner Boehringer International released a study in January concerning patients at high risk for a cardiovascular event and their brand of SGLT-2 inhibitors. The brand name of the drug, Jardiance, was shown to be superior to the current standard of care in the reduction of cardiovascular events. The study involved 7,000 adult type-2 diabetes patients considered to be at high risk for a cardiovascular event.
SLGT-2 inhibitor drugs also brought a welcome side effect of weight loss in some patients. DPP-4 inhibitors like Januvia/Janumet are weight neutral in contrast.
While it remains to be seen if SGLT-2 inhibitors will replace DPP-4 inhibitors, the FDA has released the caution that SGLT-2 inhibitors may cause a condition called ketoacidosis, or a build up of blood acids that causes hospitalization.
If you have been prescribed the diabetes drug known as Januvia, your health may have been put at risk. If you have suffered side effects or adverse health events as a result of the prescribed drug Januvia, you may be entitled to compensation. Contact the “Strong Arm” attorneys at John Foy & Associates. We may be able to help you get the compensation you deserve. Contact us today.